Vaxess Technologies
Pre-clinicalVaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $35.4M
About
Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
VaccinesDrug Delivery
Funding History
4Total raised:$35.4M
Grant$3.4MJun 15, 2022
Series B$22MSep 15, 2021
Series A$8MJun 15, 2017
Seed$2MJun 15, 2014